Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Novo Nordisk GlucaGen · 1 trial · 1 indication
The onset of action was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucose following each dose of glucagon.
The speed of absorption was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucagon following each dose of glucagon.
| Arm | Type | Description |
|---|---|---|
| G-Pump™ (glucagon infusion) | EXPERIMENTAL | G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg |
| Novo Nordisk GlucaGen® | ACTIVE_COMPARATOR | Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg |
| Name | Type | Description |
|---|---|---|
| Novo Nordisk GlucaGen® | DRUG | single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg |
| G-Pump™ (glucagon infusion) | DRUG | single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg |
Inclusion Criteria: * Males or females diagnosed with type 1 diabetes mellitus for at least 24 months * Current usage of subcutaneous insulin pump treatment * Age 18-65 years * C-peptide level \< 0.5 ng/ml * Willingness to follow all study procedures, including attending all clinic visits * Subject...
Novo Nordisk GlucaGen is used for hypoglycemia, a condition of abnormally low blood sugar. It is being developed as a treatment for this metabolic condition. The drug is currently in clinical development for this indication.
Novo Nordisk GlucaGen is being developed by Xeris Biopharma Holdings, Inc., a company traded on the stock exchange under the ticker XERS. The drug is currently in Phase 2 clinical development for the treatment of hypoglycemia.
Novo Nordisk GlucaGen is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial for the drug has been completed.
Novo Nordisk GlucaGen has one completed clinical trial, identified as NCT02081001. This was a Phase 2 study titled 'PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients,' which enrolled 19 participants with hypoglycemia in the United States.
Novo Nordisk GlucaGen is associated with the G-Pump in the context of a clinical trial. The study NCT02081001 evaluated the drug using a G-Pump glucagon infusion device in patients with type 1 diabetes and hypoglycemia.